LRRK2 and late-onset Parkinson disease: Since the abnormal enhancement of LRRK2 kinase activity is implicated in the PD-related LRRK2 mutants, including the most common G2019S mutation, extensive efforts have been devoted to the development of LRRK2 kinase inhibitors as potential therapeutic agents [10].